p53 Testing in Breast Cancer Biopsies
Author Information
Author(s): H Bonnefoi, A Ducraux, S Movarekhi, M F Pelte, S Bongard, E Lurati, R Iggo
Primary Institution: Hôpitaux Universitaires de Genève
Hypothesis
p53 mutant tumours will be anthracycline-resistant but taxane-sensitive.
Conclusion
p53 status can be reliably determined by yeast assay from trucut biopsies in breast cancer patients.
Supporting Evidence
- The yeast assay was successful on 87 out of 90 samples.
- Histological examination is essential to ensure adequate tumor cell content.
- p53 status was defined in 97% of patients by double trucut biopsy.
Takeaway
Doctors can check if a breast cancer tumor has a specific gene change using a special test on small tissue samples, which helps decide the best treatment.
Methodology
Two trucut biopsies and one incisional biopsy were performed on patients, and p53 status was assessed using a yeast functional assay.
Limitations
The study faced challenges with RNA quality and low tumor cell content in some samples.
Participant Demographics
Patients with clinically palpable breast tumors of at least 2 cm.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website